Pfizer boosted its profit outlook for the year following gains to its top- and bottom-line in its latest quarter.

The results come as Pfizer and other drugmakers grapple with Trump's calls to lower U.S. drug prices and brace for his planned tariffs on pharmaceuticals.

Pfizer Inc.’s stock was rallying Tuesday after the drug giant lifted its 2025 adjusted profit estimate, on the heels of a 10% jump in second-quarter revenue on strength in its Vyndaqel heart medication and its COVID-19 drugs.

Chief Executive Albert Bourla told analysts he is hopeful about finding a solution in response to President Trump’s demands.

Pfizer raised its full-year profit forecast on Tuesday while reporting second-quarter results that topped Wall Street estimates, and said it expects to benefit from cost-cutting and a weaker dollar. Francis Maguire reports.